Socio-hygienic aspecns of tne development of metabolic syndrome in paients witn gout nou

Objective: to study the socio-hygienic aspects of the development of metabolic syndrome, and their impact on the prevalence and course of gout. Material and methods: the study included 80 patients (78 men, 2 women) suffering from gout. The anthropometric and general characteristics of gout patients by gender, age, and duration of the disease are given. 15 patients (18.7%) were diagnosed with type 2 diabetes. The average age of patients with type 2 diabetes was (59.1 ±8.4), and the duration of the gouty history was 7.0. To identify the prevalence of gout, a questionnaire survey was conducted among the population geographically attached to primary health care institutions. Dushanbe, 200 people with a history of clinical signs of joint syndrome of varying severity. Glucose (glucose oxidase method) and uric acid (MC) levels in blood serum (colorimetric enzymatic method) were determined in all patients on an empty stomach. The blood lipid-protein spectrum was also studied – total cholesterol (HC), triglycerides (TG) and high-density lipoprotein cholesterol (HDLC) by colorimetric method. Results: men prevailed among the surveyed (97.5%). At the same time, there has been an increase in the incidence of gout among women, reflecting current annual trends in the growth of gout in women. The age of the patients varied widely, but mostly they were patients aged 40-60 (77.5%). The average age of patients with gout was 51.43±8.29 years. At the same time, the average age of women (52.8 ±2.3) was slightly higher than that of men (49.3±.52). The duration of the disease ranged from 1 month to 18 years, averaging 8.9 ±0.24. In patients younger than 50 years of age, the most common signs of MS were an increase FROM > 102cm (83.3%), an increase in blood pressure (78.2%); a slightly less common increase in serum glucose (54.1%) and a decrease in HDL-C (54.1%). Hypertriglyceridemia was observed in (28.7%). In the age group of 50-60 years, the most common signs of MS were a decrease in serum levels of HDL-C (93.2%) and an increase from > 102cm (76.7%), as well as a slight increase in the number of patients with elevated triglyceridemia (37.2%). Hypertension was more common, and an increase in hypertension, hypertriglyceridemia, and hyperglycemia were much less common than in the groups of younger patients. Naturally, the duration of the disease increased progressively with the age of the examined patients. Nevertheless, the younger the patients were, the earlier the gout debuted. It was found that in patients with gout who consumed alcohol, changes in a number of enzymes were noted: a tendency to increase the activity of transaminases, mainly ASAT, compared with patients who did not drink alcohol and those in the control group. The content of cholesterol and triglycerides in patients who abused alcoholic beverages was higher than in the comparison group. Conclusions: the data of the socio-hygienic analysis indicate a certain influence of certain factors on the prevalence, duration of the disease and the course of gout with components of MS. Among the factors that have an unfavorable value are the following: age, sedentary lifestyle, diet, alcohol abuse, smoking, overweight, obesity. This requires putting this category of people at risk of developing the disease and conducting the necessary laboratory and instrumental studies.

1. Barskova V.G. Metabolic syndrome and cardiovascular disordersin gout: dis. doctor of medical sciences. Moscow. 2006:291.

2. Barskova V.G. Chronic gout: causes of development, clinical manifestations.Ter. Arch. 2010;(1):64-68

3. Barskova V.G., Nasonova V.A. Gout and insulin resistance syndrome. Russian Medical Journal.2010;(10):291-296.

4. Bazorkina D.I., Rdes Sh. Prevalence of rheumatic diseases in the population. Scientific and practical rheumatology. 2005;(6):79-85.

5. Disanashia P.H., Didenko V.A. Is hyperuricemia a component of metabolic syndrome. Russian Journal of Cardiology. 2009;(1):28-34.

6. Eliseev M.S. et al. Clinical features of the course of gout in the elderly. Clinical gerontology.2006;12:29-33.

7. Eliseev M.S., Barskova V.G., Nasonov E.L. et al. Features of gout associated with type 2 diabetes mellitus. Clinical Gerontology. 2016;(4):7-13.

8. Zulfov D. The case of familial gout. Health care of Tajikistan. 1988;(1):97-102.

9. Ilyina A.E., Barskova V.G., Nasonov E.L. Gout, hyperuricemia and cardiovascular risk. Scientific and practical rheumatology. 2009:1

10. Mazurov V. I., Petrova M.S., Belyaeva I.B. Gout. Saint Petersburg, 2009:127

11. Kobalava Zh.D., Tolkacheva V.V., Karaulova M.L. Uric acid is a marker or a new risk factor for the development of cardiovascular complications. Breast cancer. 2002;10:10.

12. Mammadov M.N., Perova N.V., Metelskaya V.A., Ogaslov R.G. The connection of abdominal type of obesity and insulin resistance syndrome in patients with arterial hypertension. Cardiology. 1999;(3):18-22.

13. Maksudova A.N., Salikhov I.G., Khabirov R.A. Gout. Moscow: MED press inform. 2008:96

14. Petrova M.S. Metabolic disorders in gout and ways of their correction. Efferent therapy. 2007;13(1):47-49.

15. Roddy E. Changing the pharmacology of gout. National Rheumatology Clinic. 2007;(3):443-449.

16. Khabizhanov V.B. Mathematical developments in a large contract. The consultation. 2008;(1,2):44-45.

17. Choi H.K. et al. The risk of developing gout in men with type 2 diabetes mellitus and cardiovascular risk. Rheumatology. 2008; (1567):47-70.

18. Shostak N.A., Anichkov D.A. Metabolic syndrome: diagnostic criteria and possibilities of antihypertensive therapy. Russian Medical Journal. 2002;27:1258-1261.

19. Agamah E., Srinivasan S, Webber L. et al. Serum uric acid and its relstion to cardiovascular disease risk fastors in children and young adult from a biracial community: the bogulyza Heart Study J. Lab. Cllin. Med. 1991;118:241-249.

20. Angelo L., Gaffo N., Lawrence Edwards and Kenneth G. Saag. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidencefor a causal link Arthritis Research. Therapy. 2009;11;(4):240-249.

21. Ansell B.S. The metabolic syndrome: aninterplay of multiple subtle cardiovascular risk

22. Golay A., Chen Y.D., Reaven G.M. Effect of differences in glucose tolerance on insulin,s ability to regulate carbohydrate and free fatty acid 135 metabolism in obese individuals. J. Clin. Endocrinol. Metab. 1986;62:1081-1088.

23.